A 56-year-old man presents with fatigue, pallor, and abdominal pain. He reports memory loss and reveals that he works at a battery recycling plant. On examination, a noticeable foot drop in both lower extremities is seen. Laboratory testing shows elevated blood lead levels. Which enzyme is affected in the given scenario?

Explanation

## Correct Answer: B. Aminolevulinic acid (ALA) dehydratase Lead poisoning from occupational exposure (battery recycling plant) causes inhibition of **ALA dehydratase** (also called porphobilinogen synthase), the second enzyme in the heme biosynthesis pathway. This enzyme catalyzes the condensation of two molecules of δ-aminolevulinic acid (ALA) to form porphobilinogen. Lead binds to the sulfhydryl groups of cysteine residues in the enzyme's active site, causing irreversible inhibition. The clinical presentation—fatigue (anemia from impaired hemoglobin synthesis), pallor, abdominal pain (lead colic), memory loss (encephalopathy from CNS lead deposition), and bilateral foot drop (peripheral neuropathy from demyelination)—are all hallmark features of chronic lead toxicity. The elevated blood lead levels confirm the diagnosis. ALA dehydratase inhibition leads to accumulation of ALA and coproporphyrin III in urine (coproporphyrinuria), which is pathognomonic for lead poisoning. In Indian occupational settings, battery recycling workers, painters, and plumbers are at highest risk. The enzyme inhibition is dose-dependent and reversible if exposure ceases early, but chronic exposure causes permanent neurological damage. ## Why the other options are wrong **A. Uroporphyrinogen I** — Uroporphyrinogen I synthase (also called porphobilinogen deaminase) is the third enzyme in heme synthesis, not directly inhibited by lead. While lead does affect the porphyrin pathway, the primary and earliest inhibition occurs at ALA dehydratase. Uroporphyrinogen I accumulation is seen in acute intermittent porphyria, not lead poisoning. This option confuses the order of enzyme inhibition in the heme biosynthetic pathway. **C. Pyruvate dehydrogenase** — Pyruvate dehydrogenase is a mitochondrial enzyme in the citric acid cycle and is not part of heme biosynthesis. While lead does cause mitochondrial dysfunction and can affect energy metabolism, this is a secondary effect. The primary and specific enzyme inhibited by lead in the context of porphyrin metabolism is ALA dehydratase. This is a distractor testing knowledge of metabolic pathways. **D. Uroporphyrinogen III** — Uroporphyrinogen III is a substrate/intermediate in heme synthesis, not an enzyme. Uroporphyrinogen III synthase (the enzyme that produces it) is the third enzyme in the pathway. Lead's primary inhibitory target is the second enzyme (ALA dehydratase), not the third. This option confuses substrate with enzyme and tests whether students understand the sequential nature of heme biosynthesis. ## High-Yield Facts - **ALA dehydratase inhibition** is the earliest and most sensitive marker of lead toxicity, detectable at blood lead levels >10 µg/dL. - **Coproporphyrinuria** (elevated urinary coproporphyrin III) is pathognomonic for lead poisoning and results from ALA dehydratase inhibition. - **Bilateral foot drop** in lead poisoning indicates **motor neuropathy** affecting the radial and peroneal nerves; sensory nerves are spared. - **Lead colic** (severe abdominal pain) is caused by lead's effect on smooth muscle and is reversible with chelation therapy. - **Blood lead levels >40 µg/dL** in adults warrant chelation therapy; occupational exposure limit in India is 50 µg/dL (DGMS guidelines). - **Heme biosynthesis inhibition** by lead causes microcytic anemia with basophilic stippling of RBCs on peripheral smear. ## Mnemonics **LEAD Poisoning Pathway (Heme Synthesis)** **L**evels of ALA ↑ → **E**nzyme ALA dehydratase ↓ → **A**nemia + **D**amage (neuro/renal). Remember: Lead hits the 2nd enzyme (ALA dehydratase) → ALA accumulates → coproporphyrinuria. **Lead Toxicity Triad** **Neuro** (encephalopathy, foot drop, neuropathy) + **Heme** (anemia, basophilic stippling) + **Renal** (chronic kidney disease). ALA dehydratase inhibition is the biochemical link. ## NBE Trap NBE pairs lead poisoning with porphyrin pathway enzymes to test whether students know the *sequence* of heme biosynthesis. The trap is offering Uroporphyrinogen I/III (3rd enzyme or substrate) to lure students who know "lead affects porphyrins" but don't recall that ALA dehydratase (2nd enzyme) is the primary target. ## Clinical Pearl In Indian battery recycling and informal e-waste dismantling units, lead poisoning is endemic. A worker presenting with "foot drop + memory loss + anemia" is lead poisoning until proven otherwise. Urinary coproporphyrin III is the bedside screening test (elevated in >95% of symptomatic cases) and is cheaper than blood lead measurement in resource-limited Indian settings. _Reference: Robbins Ch. 9 (Environmental and Nutritional Pathology); KD Tripathi Ch. 57 (Heavy Metal Poisoning); Park's Textbook of Preventive and Social Medicine Ch. 10 (Occupational Health)_